Effect of the tyrosine kinase inhibitors on the growth in children with Philadelphia chromosome–positive acute lymphoblastic leukemia: a case–control study

Lancet Regional Health - Western Pacific, The - Tập 38 - Trang 100818 - 2023
Jiaoyang Cai1, Hu Liu2, Yumei Chen3, Jie Yu4, Ju Gao5, Hua Jiang6, Xiaowen Zhai7, Xiuli Ju8, Xuedong Wu9, Ningling Wang10, Xin Tian11, Changda Liang12, Yongjun Fang13, Fen Zhou14, Hong Li15, Lirong Sun16, Liangchun Yang17, Jing Guo18, Aiguo Liu19, Chi-kong Li20
1Department of Hematology/Oncology, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine, Key Laboratory of Pediatric Hematology & Oncology of China Ministry of Health, and National Children’s Medical Center, Shanghai, China
2Department of Hematology & Oncology, Children’s Hospital of Soochow University, Suzhou, China
3Department of Pediatrics, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4Department of Hematology/Oncology, Chongqing Medical University Affiliated Children's Hospital, Chongqing, China
5Department of Pediatrics, West China Second University Hospital, Sichuan University, Key Laboratory of Birth Defects and Related Disease of Women and Children, Ministry of Education, Chengdu, China
6Department of Hematology/Oncology, Guangzhou Women and Children’s Medical Center, Guangzhou, China
7Department of Hematology oncology, Children’s hospital of Fudan university, Shanghai, China
8Department of Pediatrics, Qilu Hospital of Shandong University, Jinan, China
9Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China
10Department of Pediatrics, Anhui Medical University Second Affiliated Hospital, Anhui, China
11Department of Hematology/Oncology, Kunming Children’s Hospital, Kunming, China
12Department of Hematology/Oncology, Jiangxi Provincial Children’s Hospital, Nanchang, China
13Department of Hematology/Oncology, Children's Hospital of Nanjing Medical University, Nanjing, China
14Department of Pediatrics, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
15Department of Hematology/Oncology, Shanghai Children's Hospital, Shanghai, China
16Department of Pediatrics, Affiliated Hospital of Qingdao University, Qingdao, China
17Department of Pediatrics, Xiangya Hospital, Central South University, Changsha, China
18Department of Hematology/Oncology, Xi 'an Northwest Women's and Children's Hospital, Xi 'an, China
19Department of Pediatrics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
20Department of Pediatrics, Hong Kong Children’s Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China

Tài liệu tham khảo

Pui, 2015, Childhood acute lymphoblastic leukemia: progress through collaboration, J Clin Oncol, 33, 2938, 10.1200/JCO.2014.59.1636 Hunger, 2015, Acute lymphoblastic leukemia in children, N Engl J Med, 373, 1541, 10.1056/NEJMra1400972 Pieters, 2016, Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch childhood oncology group, J Clin Oncol, 34, 2591, 10.1200/JCO.2015.64.6364 Vrooman, 2018, Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001, Blood Adv, 2, 1449, 10.1182/bloodadvances.2018016584 Dalton, 2003, Height and weight in children treated for acute lymphoblastic leukemia: relationship to CNS treatment, J Clin Oncol, 21, 2953, 10.1200/JCO.2003.03.068 Vandecruys, 2013, Longitudinal linear growth and final height is impaired in childhood acute lymphoblastic leukemia survivors after treatment without cranial irradiation, J Pediatr, 163, 268, 10.1016/j.jpeds.2012.12.037 Browne, 2018, Changes in body mass index, height, and weight in children during and after therapy for acute lymphoblastic leukemia, Cancer, 124, 4248, 10.1002/cncr.31736 Shima, 2011, Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia, J Pediatr, 159, 676, 10.1016/j.jpeds.2011.03.046 Rastogi, 2012, Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia, Pediatr Blood Cancer, 59, 840, 10.1002/pbc.24121 Bansal, 2012, Imatinib has adverse effect on growth in children with chronic myeloid leukemia, Pediatr Blood Cancer, 59, 481, 10.1002/pbc.23389 Millot, 2014, Growth deceleration in children treated with imatinib for chronic myeloid leukaemia, Eur J Cancer, 50, 3206, 10.1016/j.ejca.2014.10.007 Sabnis, 2019, Growth disturbances in children and adolescents receiving long-term tyrosine kinase inhibitor therapy for Chronic Myeloid Leukaemia or Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia, Br J Haematol, 185, 795, 10.1111/bjh.15633 Boddu, 2019, Effect of imatinib on growth in children with chronic myeloid leukemia, Pediatr Hematol Oncol, 36, 189, 10.1080/08880018.2019.1610119 Cai, 2021, Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: single-center experience from China, Int J Hematol, 113, 413, 10.1007/s12185-020-03042-1 Patterson, 2019, HemaSphere, 3, 161, 10.1097/01.HS9.0000559876.36369.09 Zheng, 2020, Impact of tyrosine kinase inhibitors on the statural growth in children with acute lymphoblastic leukemia, Leuk Res, 95, 10.1016/j.leukres.2020.106405 Shen, 2020, Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial, JAMA Oncol, 6, 358, 10.1001/jamaoncol.2019.5868 Tang, 2021, Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation, Blood, 138, 331, 10.1182/blood.2020010438 Yang, 2021, Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial, Lancet Oncol, 22, 1322, 10.1016/S1470-2045(21)00328-4 Pui, 2009, Treating childhood acute lymphoblastic leukemia without cranial irradiation, N Engl J Med, 360, 2730, 10.1056/NEJMoa0900386 Jeha, 2019, Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude total therapy study 16, J Clin Oncol, 37, 3377, 10.1200/JCO.19.01692 Liu, 2009, Cost of childhood acute lymphoblastic leukemia care in Shanghai, China, Pediatr Blood Cancer, 53, 557, 10.1002/pbc.22127 Shen, 2018, Long-term results of the risk-stratified treatment of childhood acute lymphoblastic leukemia in China, Hematol Oncol, 36, 679, 10.1002/hon.2541 Jabbour, 2018, Efficacy of ponatinib versus earlier generation tyrosine kinase inhibitors for front-line treatment of newly diagnosed Philadelphia-positive acute lymphoblastic leukemia, Clin Lymphoma Myeloma Leuk, 18, 257, 10.1016/j.clml.2018.02.010 Foà, 2020, GIMEMA investigators. Dasatinib-blinatumomab for ph-positive acute lymphoblastic leukemia in adults, N Engl J Med, 383, 1613, 10.1056/NEJMoa2016272 Slayton, 2018, Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of Children's oncology group trial AALL0622, J Clin Oncol, 36, 2306, 10.1200/JCO.2017.76.7228 Hunger, 2017, CA180-372: an international collaborative phase 2 trial of dasatinib and chemotherapy in pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), Blood, 130, 98, 10.1182/blood.V130.Suppl_1.98.98 Gong, 2021, A higher dose of dasatinib may increase the possibility of crossing the blood-brain barrier in the treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, Clin Ther, 43, 1265, 10.1016/j.clinthera.2021.05.009 Berman, 2006, Altered bone and mineral metabolism in patients receiving imatinib mesylate, N Engl J Med, 354, 2006, 10.1056/NEJMoa051140 Jönsson, 2008, Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia, Haematologica, 93, 1101, 10.3324/haematol.12373 Narayanan, 2013, Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis, Pediatr Blood Cancer, 60, 1148, 10.1002/pbc.24397 Samis, 2016, Recognizing endocrinopathies associated with tyrosine kinase inhibitor therapy in children with chronic myelogenous leukemia, Pediatr Blood Cancer, 63, 1332, 10.1002/pbc.26028 Hijiya, 2019, How I treat chronic myeloid leukemia in children and adolescents, Blood, 133, 2374, 10.1182/blood.2018882233 Gambacorti-Passerini, 2003, Gynaecomastia in men with chronic myeloid leukaemia after imatinib, Lancet, 361, 1954, 10.1016/S0140-6736(03)13554-4 Haouala, 2011, Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib, Blood, 117, e75, 10.1182/blood-2010-07-294330
Thông tin
Thông tin xuất bản

Lancet Regional Health - Western Pacific, The

Tập 38

100818

Thông tin tác giả